- Home
- XERS vs REPL Comparison
XERS vs REPL Comparison
Compare XERS & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XERS
- REPL
- Stock Information
- Founded
- XERS 2005
- REPL 2015
- Country
- XERS United States
- REPL United States
- Employees
- XERS N/A
- REPL N/A
- Industry
- XERS Biotechnology: Pharmaceutical Preparations
- REPL Biotechnology: Pharmaceutical Preparations
- Sector
- XERS Health Care
- REPL Health Care
- Exchange
- XERS Nasdaq
- REPL Nasdaq
- Market Cap
- XERS 752.7M
- REPL 757.8M
- IPO Year
- XERS 2018
- REPL 2018
- Fundamental
- Price
- XERS $5.11
- REPL $11.09
- Analyst Decision
- XERS Strong Buy
- REPL Strong Buy
- Analyst Count
- XERS 6
- REPL 7
- Target Price
- XERS $6.25
- REPL $20.83
- AVG Volume (30 Days)
- XERS 2.0M
- REPL 1.3M
- Earning Date
- XERS 08-07-2025
- REPL 08-07-2025
- Dividend Yield
- XERS N/A
- REPL N/A
- EPS Growth
- XERS N/A
- REPL N/A
- EPS
- XERS N/A
- REPL N/A
- Revenue
- XERS $222,551,000.00
- REPL N/A
- Revenue This Year
- XERS $35.03
- REPL N/A
- Revenue Next Year
- XERS $18.31
- REPL N/A
- P/E Ratio
- XERS N/A
- REPL N/A
- Revenue Growth
- XERS 29.88
- REPL N/A
- 52 Week Low
- XERS $2.10
- REPL $6.44
- 52 Week High
- XERS $6.07
- REPL $17.00
- Technical
- Relative Strength Index (RSI)
- XERS 61.48
- REPL 68.18
- Support Level
- XERS $4.62
- REPL $9.26
- Resistance Level
- XERS $5.39
- REPL $9.90
- Average True Range (ATR)
- XERS 0.21
- REPL 0.59
- MACD
- XERS 0.07
- REPL 0.14
- Stochastic Oscillator
- XERS 71.72
- REPL 91.56
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.